Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Equivalents (2016 - 2026)

Summit Therapeutics filings provide 13 years of Cash & Equivalents readings, the most recent being $106.5 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 49.64% to $106.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $106.5 million through Mar 2026, down 49.64% year-over-year, with the annual reading at $225.3 million for FY2025, 114.82% up from the prior year.
  • Cash & Equivalents hit $106.5 million in Q1 2026 for Summit Therapeutics, down from $225.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $348.6 million in Q4 2022 and bottomed at $23.8 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $136.5 million, with a median of $104.9 million recorded in 2024.
  • The largest annual shift saw Cash & Equivalents plummeted 80.49% in 2023 before it soared 947.59% in 2025.
  • Summit Therapeutics' Cash & Equivalents stood at $348.6 million in 2022, then crashed by 79.51% to $71.4 million in 2023, then skyrocketed by 46.81% to $104.9 million in 2024, then soared by 114.82% to $225.3 million in 2025, then crashed by 52.72% to $106.5 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Cash & Equivalents are $106.5 million (Q1 2026), $225.3 million (Q4 2025), and $238.6 million (Q3 2025).